Preliminary Final Report
Filed with ASX · · 61 pages · English
Summary by 6ix AI
The report indicates a record revenue growth driven by increased sales in the U.S. market, which has become the company's largest individual market for Technegas. Despite the revenue growth, the company reported a significant loss after tax, reflecting ongoing investments to support U.S. expansion. No dividends have been proposed for the current period, as the focus remains on growth and market penetration.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Cyclopharm
- Technegas US Footprint Expanding Across Four Regions
- Technegas Approved at the US National Institutes of Health
- Cyclopharm Capital Raising Investor Presentation
- Cyclopharm Successfully Completes A$14 million Placement
- CYC Unaudited Trading Update - Preliminary FY2025 Results
Later from Cyclopharm
- CYC Signs Enterprise Agreement with UPHS
- CYC Secures Multi-Site Agreement with Northwestern Medicine
- USA Technegas Expansion Update
- CYC First-Half 2026 Update
- Immediate 11-Site Technegas Rollout at University Hospitals
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm